The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Temozolomide

Temozolomide

Temozolomide is an alkylating chemotherapy agent used in the treatment of certain types of brain tumors, particularly glioblastoma multiforme.
It works by damaging the DNA of cancer cells, leading to their death.
Temozolomide is commonly used in combination with radiation therapy and other chemotherapeutic drugs to improve treatment outcomes.
Researchers continually explore new protocols and approaches to optimize the use of Temozolomide and enhance its effectiveness, reproducibility, and research accuracy.
The PubCompare.ai tool leverages AI-driven comparisons to help users effortlessly locate the best Temozolomide protocols from literature, pre-prints, and patents, supporting advancements in this important area of cancer research.

Most cited protocols related to «Temozolomide»

SignatureAnalyzer uses a Bayesian variant of NMF that infers the number of signatures through the automatic relevance determination technique and delivers highly interpretable and sparse representations for both signature profiles and attributions that strike a balance between data fitting and model complexity. Further details of the actual implementation of the computational approach have previously been published9 (link),27 (link),64 (link). SignatureAnalyzer was applied by using a two-step signature extraction strategy using 1,536 pentanucleotide contexts for SBSs, 83 indel features and 78 DBS features. In addition to the separate extraction of SBS, indel and DBS signatures, we performed a ‘COMPOSITE’ signature extraction based on all 1,697 features (1,536 SBS + 78 DBS + 83 indel). For SBSs, the 1,536 SBS COMPOSITE signatures are preferred; for DBSs and indels, the separately extracted signatures are preferred.
In step 1 of the two-step extraction process, global signature extraction was performed for the samples with a low mutation burden (n = 2,624). These excluded hypermutated tumours: those with putative polymerase epsilon (POLE) defects or mismatch repair defects (microsatellite instable tumours), skin tumours (which had intense UV-light mutagenesis) and one tumour with temozolomide (TMZ) exposure. Because the underlying algorithm of SignatureAnalyzer performs a stochastic search, different runs can produce different results. In step 1, we ran SignatureAnalyzer 10 times and selected the solution with the highest posterior probability. In step 2, additional signatures unique to hypermutated samples were extracted (again selecting the highest posterior probability over ten runs) while allowing all signatures found in the samples with low mutation burden, to explain some of the spectra of hypermutated samples. This approach was designed to minimize a well-known ‘signature bleeding’ effect or a bias of hyper- or ultramutated samples on the signature extraction. In addition, this approach provided information about which signatures are unique to the hypermutated samples, which was later used when attributing signatures to samples.
A similar strategy was used for signature attribution: we performed a separate attribution process for low- and hypermutated samples in all COMPOSITE, SBS, DBS and indel signatures. For downstream analyses, we preferred to use the COMPOSITE attributions for SBSs and the separately calculated attributions for DBSs and indels. Signature attribution in samples with a low mutation burden was performed separately in each tumour type (for example, Biliary–AdenoCA, Bladder–TCC, Bone–Osteosarc, and so on). Attribution was also performed separately in the combined microsatellite instable tumours (n = 39), POLE (n = 9), skin melanoma (n = 107) and TMZ-exposed samples (syn11738314). In both groups, signature availability (which signatures were active, or not) was primarily inferred through the automatic relevance determination process applied to the activity matrix H only, while fixing the signature matrix W. The attribution in samples with a low mutation burden was performed using only signatures found in the step 1 of the signature extraction. Two additional rules were applied in SBS signature attribution to enforce biological plausibility and minimize a signature bleeding: (i) allow SBS4 (smoking signature) only in lung, head and neck cases; and (ii) allow SBS11 (TMZ signature) in a single GBM sample. This was enforced by introducing a binary, signature-by-sample signature indicator matrix Z (1, allowed; 0, not allowed), which was multiplied by the H matrix in every multiplication update of H. No additional rules were applied to indel or DBS signature attributions, except that signatures found in hypermutated samples were not allowed in samples with a low mutation burden.
Full text: Click here
Publication 2020
Bile Biopharmaceuticals Bones Familial Atypical Mole-Malignant Melanoma Syndrome Head INDEL Mutation Lung Microsatellite Instability Mismatch Repair Mutagenesis Mutation Neck Neoplasms Skin Neoplasms Temozolomide Ultraviolet Rays Urinary Bladder

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Congenital Abnormality EGFR protein, human Germ Cells Glioblastoma Mesenchyma Mus Patients Radiotherapy Temozolomide
To determine the cytotoxicity of chemotherapy drugs, cell growth/viability was measured using an acid phosphatase assay; 1.5–3 × 103 cells were seeded in flat-bottomed 96-well plates and incubated overnight prior to addition of drug. Chemotherapeutics were obtained from St Vincent’s University Hospital, Dublin, Ireland. Lapatinib was purchased from Sequoia. Temozolomide was obtained from the National Cancer Institute. Other inhibitors and modulators were obtained from Sigma. Drug-free controls were included in each assay. Plates were incubated for a further 5 (HCC1954, Malme-3M and HT144) or 7 days (H1299 and H460) at 37°C in a humidified atmosphere with 5% CO2 and cell viability was determined using an acid phosphatase assay (97 (link)). Growth of drug-treated cells was calculated relative to control untreated cells in biological triplicate.
Full text: Click here
Publication 2014
Acid Phosphatase Atmosphere Biological Assay Biopharmaceuticals Cells Cell Survival Cytotoxin inhibitors Lapatinib Pharmaceutical Preparations Pharmacotherapy Sequoia Temozolomide
Patients were eligible for inclusion in the study if they had a diagnosis of unresectable stage III or IV melanoma and had received a previous therapeutic regimen containing one or more of the following: dacarbazine, temozolomide, fotemustine, carboplatin, or interleukin-2. Other inclusion criteria were age of at least 18 years; life expectancy of at least 4 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0 (fully active, able to carry on all predisease performance without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work)24 (link); positive status for HLA-A⋆0201; normal hematologic, hepatic, and renal function; and no systemic treatment in the previous 28 days. Exclusion criteria were any other cancer from which the patient had been disease-free for less than 5 years (except treated and cured basal-cell or squamous-cell skin cancer, superficial bladder cancer, or treated carcinoma in situ of the cervix, breast, or bladder); primary ocular melanoma; previous receipt of anti–CTLA-4 antibody or cancer vaccine; autoimmune disease; active, untreated metastases in the central nervous system; pregnancy or lactation; concomitant treatment with any nonstudy anticancer therapy or immunosuppressive agent; or long-term use of systemic corticosteroids.
The protocol was approved by the institutional review board at each participating institution and was conducted in accordance with the ethical principles originating from the Declaration of Helsinki and with Good Clinical Practice as defined by the International Conference on Harmonization. All patients (or their legal representatives) gave written informed consent before enrollment.
Publication 2010
Adrenal Cortex Hormones Antibodies, Anti-Idiotypic Autoimmune Diseases Breast Breast Feeding Cancer Vaccines Carboplatin Cells Central Nervous System Cervical Intraepithelial Neoplasia, Grade III Conferences Cytotoxic T-Lymphocyte Antigen 4 Dacarbazine Diagnosis Ethics Committees, Research Eye fotemustine Immunosuppressive Agents Interleukin-2 Kidney Light Malignant Neoplasms Melanoma Neoplasm Metastasis Neoplasms Non-Muscle Invasive Bladder Neoplasms Patients Pregnancy Skin Squamous Cell Carcinoma Temozolomide Therapeutics Treatment Protocols Urinary Bladder
p16-3MR mice (15 (link)) were maintained in the AALAC-accredited Buck Institute for Research on Aging (Novato, CA, USA) animal facility. All procedures were approved by the Institutional Animal Care and Use Committee. p16-3MR mice were bred in-house. For in vivo luminescence and tissue extraction, both male and female mice were used. For all the other experiments, female mice were used. For Doxo treatments, 10–16 wk old p16-3MR mice were injected intraperitoneal (i.p.) once with 2, 10 or 25 mg/kg of doxorubicin hydrochloride (Sigma Aldrich) in PBS, and treated 5 d later with vehicle or GCV. GCV was administered via daily i.p. injections for 5 consecutive days at 25 mg/kg in PBS. Control mice were injected with an equal volume of PBS. For Paclitaxel treatments, 10–16 wk old p16-3MR mice were injected 3 times i.p. with 10 mg/kg of Paclitaxel (Sigma Aldrich) in PBS/5% DMSO, and treated 5 days later with vehicle or GCV. GCV was administered via daily i.p. injections for 5 consecutive days at 25 mg/kg in PBS. Control mice were injected with an equal volume of PBS. For Temozolomide treatments, 10–16 wk old p16-3MR mice were injected 3 times i.p. with 50 mg/kg (Sigma Aldrich) in PBS/5% DMSO/0.1% Tween. For Cisplatin treatments, 10–16 wk old p16-3MR mice were injected 3 times i.p. with 2.3 mg/kg (Enzo Life Sciences, Farmingdale NY, USA) in PBS/1% DMSO.
MMTV-PyMT-fLUC cells (105) were injected into the inguinal mammary fat pad. Surgical removal was done under total body anesthesia (isofluorane), and wounds were closed with metal stitches. Analgesia was injected subcutaneously pre-surgery and up to 48 hours post-surgery (buprenorphine).
Publication 2016
Anesthesia Animals Buprenorphine Cells Cisplatin Females Groin Human Body Hydrochloride, Doxorubicin Institutional Animal Care and Use Committees Luminescence Males Mammary Gland Management, Pain Metals Mice, House Mouse mammary tumor virus Operative Surgical Procedures Paclitaxel Pad, Fat Sulfoxide, Dimethyl Temozolomide Tissues Tweens Wounds

Most recents protocols related to «Temozolomide»

Example 40

Compounds linked to the temozolomide component are synthesized as follows. The iodo acid [7425-27-6] is reacted with a cannabinoid (CBD) under standard esterification conditions to give the iodo ester intermediate. Following conditions (see Scheme) similar to those published for the synthesis of temozolomide from iodomethane, the desired cannabinoid conjugate component is produced by N-alkylation of [108030-65-5]. A cannabinoid conjugate component comprising two temozolomide components may also be obtained.

[Figure (not displayed)]

Alternatively, the heterocycle first can be alkylated with an iodo ester. The ester is then removed, and the heterocycle is esterified with CBD to form the cannabinoid-temozolomide conjugate component.

Building block [108030-65-5] can be obtained commercially or synthesized, for example using the published two-step route shown below (Bioorganic & Medicinal Chemistry Letters 6, 185-88, 1996):

[Figure (not displayed)]

Full text: Click here
Patent 2024
Acids Alkylation Anabolism Cannabinoids Esterification Esters Iodine methyl iodide Temozolomide

Example 7

An amount of any one of the compounds of the present invention in combination with an anti-cancer agent is administered to a subject afflicted with brain cancer. The amount of the compound is effective to enhance the anti-cancer activity of the anti-cancer agent.

An amount of any one of the compounds of the present invention in combination with ionizing radiation, x-radiation, docetaxel or temozolomide is administered to a subject afflicted with brain cancer. The amount of the compound is effective to enhance the anti-cancer activity of the ionizing radiation, x-radiation, docetaxel or temozolomide.

An amount of any one of the compounds of the present invention in combination with an anti-cancer agent is administered to a subject afflicted with diffuse intrinsic pontine glioma or glioblastoma multiforme. The amount of the compound is effective to enhance the anti-cancer activity of the anti-cancer agent.

An amount of any one of the compounds of the present invention in combination with ionizing radiation, x-radiation, docetaxel or temozolomide is administered to a subject afflicted with diffuse intrinsic pontine glioma or glioblastoma multiforme. The amount of the compound is effective to enhance the anti-cancer activity of the ionizing radiation, x-radiation, docetaxel or temozolomide.

Full text: Click here
Patent 2024
Brain Neoplasm, Malignant Diffuse Intrinsic Pontine Glioma Docetaxel Glioblastoma Multiforme Malignant Neoplasms Radiation, Ionizing Roentgen Rays Temozolomide
A retrospective analysis was made of 26 patients who were newly diagnosed or had recurrent high-grade glioma treated in the Department of Radiotherapy of Jinling Hospital from 2017 to 2022.
Inclusion criteria: 1) Karnofsky Performance Scale (KPS) ≥60; 2) age ≥ 18 years old; 3) pathologically confirmed as World Health Organization Level IV glioblastoma (GBM); 4) recurrence after magnetic resonance imaging (MRI) review (including MR spectroscopy (MRS) and perfusion imaging) is assessed by surgeons, radiologists, and oncologists according to Response Assessment in Neuro-Oncology (RANO) criteria; 5) measurable lesions; 6) good bone marrow, liver, and kidney functions; 7) anlotinib combined with dose-intensive temozolomide (TMZ) in the treatment of relapse; 8) previous standard concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy (AC).
Exclusion criteria: 1) complications of other malignant tumors or serious diseases; 2) patients with hypertension whose blood pressure still cannot be reduced to the normal range after treatment with antihypertensive drugs, patients with grade I and above myocardial ischemia or myocardial infarction, and arrhythmias (including QT interval ≥440 ms), patients with grade II cardiac insufficiency, and patients with arteriovenous thrombosis, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, and pulmonary embolism within 6 months; 3) lack of follow-up data.
All the patients were younger than 75 years old and their KPS scores were above 60 points. Anlotinib was taken orally during postoperative concurrent chemoradiotherapy or after relapse. It was used as 12 mg once a day for 2 weeks and stopped for 1 week. Efficacy was evaluated according to the RANO criteria, and the cranial MR examination was conducted every 1–3 months. According to the MR results and clinical symptoms, the efficacy was divided into complete remission (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The overall response rate (ORR) means CR and PR. The DCR means CR, PR, and SD. The primary study endpoints were PFS at 6 months and OS at 1 year (both were calculated at the start of anlotinib treatment).
Full text: Click here
Publication 2023
Aftercare anlotinib Antihypertensive Agents Blood Pressure Bone Marrow Cardiac Arrhythmia Cerebrovascular Accident Chemotherapy, Adjuvant Concurrent Chemoradiotherapy Cranium Deep Vein Thrombosis Glioblastoma Heart Failure High Blood Pressures Kidney Liver Magnetic Resonance Spectroscopy Malignant Glioma Malignant Neoplasms Myocardial Infarction Myocardial Ischemia Neoplasms Oncologists Patients Pulmonary Embolism Radiologist Radiotherapy Recurrence Relapse Surgeons Temozolomide Thrombosis Transient Ischemic Attack Youth
We recruited adult patients admitted to Addenbrooke’s hospital between May 2017 and January 2020 in an ethically approved study investigating longitudinal cognitive function in patients with glioblastoma (Harrow Research Ethics Committee: 18/LO/0491). Written informed consent was obtained from all patients. All procedures were in accordance with the Declaration of Helsinki. Inclusion criteria were (i) diagnosis of glioblastoma, (ii) intended surgical removal of at least 90% of the enhancing tumour, (iii) suitable for subsequent radiotherapy (60 Gray) with concomitant Temozolomide, (iv) World Health Organization performance status of zero or one, and (v) intact capacity for longitudinal cognitive testing before and after surgery. A sampling strategy of recruiting all consecutive potential participants that met the inclusion criteria was employed.
Full text: Click here
Publication 2023
Adult Cognition Diagnosis Ethics Committees, Research Glioblastoma Neoplasms Operative Surgical Procedures Patients Radiotherapy Temozolomide
Brain tumor implantation in the forebrain (50,000 to 100,000 cells), cranial window surgery, and tumor resection as part of the SOC treatment regimen were conducted as previously described (17 (link), 52 (link), 53 (link)). Mice were allowed to recover for 10 to 14 d after cranial window surgery prior to tumor implantation and for 2 d after resection surgery (as part of the SOC or bihemispheric model) prior to treatment initiation.
When tumors reached 1 mm in diameter (7 to 10 d post-implantation), mice were treated daily with phosphate-buffered saline (PBS;control) or losartan (Selleckchem) daily at 60 mg/kg until study endpoint. After 1 wk of losartan pretreatment, mice were treated with IgG (control) or anti-PD1 (BioxCell, RMP1-14) every 3 d for three doses at 200 μg/mouse. SOC mice received concurrently with losartan: 5 d of consecutive radiotherapy (2 Gy/d) and 10 d of consecutive chemotherapy (temozolomide, Selleckchem) at 25 mg/kg. All drugs were injected i.p. For flow cytometry, scRNASeq, intravital imaging, histology, and edema measurements, mice were imaged/sacrificed after the third dose of anti-PD1 and/or 2 wk of losartan treatment.
Full text: Click here
Publication 2023
Brain Neoplasms Cells Cranium Edema Flow Cytometry Losartan Mus Neoplasms Operative Surgical Procedures Ovum Implantation Pharmaceutical Preparations Pharmacotherapy Phosphates Prosencephalon Radiotherapy Saline Solution Single-Cell RNA-Seq Temozolomide Treatment Protocols

Top products related to «Temozolomide»

Sourced in United States, Germany, United Kingdom, Italy, Sao Tome and Principe, Switzerland
Temozolomide is a chemical compound used in laboratory research. It is a white to off-white crystalline powder. Temozolomide is soluble in water and dimethyl sulfoxide.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, Germany, China, Italy, Macao, Ireland
Temozolomide (TMZ) is a pharmaceutical product manufactured by Merck Group. It functions as a chemotherapeutic agent used in the treatment of certain types of brain cancers. TMZ is a synthetic alkylating agent that interferes with DNA replication, leading to cell death in rapidly dividing cells.
Sourced in United States, Germany
Temozolomide is a powdered chemical product used in laboratory research settings. It is a white to off-white crystalline solid. Temozolomide is commonly utilized in experimental procedures and scientific investigations, but its specific core function should not be extrapolated upon without further details.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal
Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.
Sourced in United States, Germany, United Kingdom, China, France, Japan
Olaparib is a laboratory chemical product. It is a poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib functions by inhibiting the activity of PARP enzymes, which are involved in DNA repair processes.
Sourced in United States, China, Italy, Germany, Japan, United Kingdom
U87MG is a human glioblastoma cell line derived from a malignant brain tumor. It is a well-established model system used in cancer research and drug discovery studies.

More about "Temozolomide"

Temozolomide (TMZ) is a potent alkylating chemotherapy agent used in the treatment of various brain tumors, particularly glioblastoma multiforme (GBM).
This DNA-damaging drug works by inducing cell death in cancer cells, making it a crucial component of many cancer treatment protocols.
Researchers continually explore new approaches to optimize the use of Temozolomide, such as combining it with radiation therapy, other chemotherapeutic drugs (e.g., Cisplatin, Olaparib), and cell culture media (e.g., DMEM, FBS, Penicillin/streptomycin, DMSO) to enhance its effectiveness, reproducibility, and research accuracy.
The PubCompare.ai tool leverages AI-driven comparisons to help users effortlessly locate the best Temozolomide protocols from literature, pre-prints, and patents, supporting advancements in this important area of cancer research.
By exploring these optimized protocols, researchers can improve treatment outcomes and advance the understanding of Temozolomide's mechanisms of action in tackling brain tumors like the U87MG cell line.
The power of AI-assisted protocol selection can make a significant impact in the field of Temozolomide research and cancer therapeutics.